Loading stock data…
Vanda Pharmaceuticals Inc. (VNDA)
N/A
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide.
Historical Price
No chart data available for VNDA
Whystock Brain
The Narrative
Vanda Pharmaceuticals Inc. in the Healthcare sector is trading at $6.14 with a market capitalization of $388M. Wall Street consensus targets $14.12 (4 analysts), implying a +130.0% move over the next 12 months. The stock is currently 38% below its 52-week high of $9.94, remaining 4.7% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 25/100 signals elevated caution as multiple indicators diverge.
Ecosystem Influences
Sell-side targets imply +130.0% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $51.72M↓ | $57.22M↑ | $56.26M↑ | $52.59M↑ | $50.04M |
| Gross Profit | $48.56M↓ | $53.38M↑ | $53.30M↑ | $49.85M↑ | $46.52M |
| Operating Income | -$50.22M↓ | -$40.35M↓ | -$31.28M↑ | -$38.50M↑ | -$41.03M |
| Net Income | -$48.57M↑ | -$141.19M↓ | -$22.59M↑ | -$27.21M↑ | -$29.49M |
Peer Comparison
JNJUNHPFE
Fundamentals
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's commercial portfolio includes Fanapt for the acute treatment of manic ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$387.87M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.65
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-67.38%
Volume
Today's trading volume
-
Recent News
How The Vanda Pharmaceuticals (VNDA) Investment Story Is Shifting With BYSANTI And Nereus
Vanda Pharmaceuticals is back in focus after a fair value price target update to US$14.90 from US$12.67, reflecting refreshed assumptions in analyst models. Recent research is split, with some analysts pointing to upside from BYSANTI and other commercial assets, while others are trimming expectations as they reassess how quickly the story can play out. As you read on, you will see how to track this evolving narrative and what to watch as new information comes through. Stay updated as the Fair...
Is AnaptysBio (ANAB) One of the Best Performing Healthcare Stocks so Far in 2026?
AnaptysBio, Inc. (NASDAQ:ANAB) is one of the best performing healthcare stocks so far in 2026. Piper Sandler cut the price target on AnaptysBio, Inc. (NASDAQ:ANAB) to $93 from $95 on May 4, reaffirming an Overweight rating on the shares. The firm stated that the company announced in April 2026 the completion of the First Tracks […]
Vanda Pharmaceuticals Q1 Earnings Call Highlights
Vanda Pharmaceuticals (NASDAQ:VNDA) reported first-quarter 2026 revenue of $51.7 million, a 3% increase from $50.0 million in the prior-year period, as growth in Fanapt was partially offset by continued declines in HETLIOZ amid generic competition. Management also highlighted the U.S. commercial lau
Vanda Pharmaceuticals Inc. Q1 2026 Earnings Call Summary
Moby summary of Vanda Pharmaceuticals Inc.'s Q1 2026 earnings call
Vanda (VNDA) Q1 2026 Earnings Call Transcript
Kevin Moran: Thank you, Jordan. Good afternoon, and thank you for joining us to discuss Vanda Pharmaceuticals Inc.’s first quarter 2026 performance. Joining me on today’s call is Mihael H. Polymeropoulos, our President, Chief Executive Officer, and Chairman of the Board.